

Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016

May 9, 2016 4:30 PM ET

Poster to highlight positive Phase I data for ROR γ t inhibitor VTP-43742

FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President of Biology, will present a poster titled "Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a ROR γ t inhibitor, in normal healthy volunteers" at IMMUNOLOGY 2016, the American Association of Immunologists' annual meeting, to be held May 13-17, 2016 in Seattle.

VTP-43742 is Vitae's wholly owned, first-in-class, orally active ROR γ t inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, through the potent inhibition of IL-17 secretion from Th17 cells and blocking the action of IL-23.

The poster details are as follows:

Title: "Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a ROR γ t inhibitor, in normal healthy volunteers"

Session: Late-Breaking Therapeutic Approaches to Autoimmunity

Poster: #P2282

Date: Saturday, May 14, 2016

Time: 2:30 to 3:45 p.m. PDT

Location: Washington State Convention Center, Exhibit / Poster Hall

For more information on IMMUNOLOGY 2016, please visit <http://www.immunology2016.org/>.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae's lead clinical assets include VTP-43742, an oral ROR γ t inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXR β selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company's website at www.vitaepharma.com.

INVESTORS:

Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com

Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com

MEDIA:

6 Degrees PR
Tony Plohoros
(908) 591-2839
tplohoros@6degreespr.com



Vitae Pharmaceuticals, Inc.